These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 33545267)

  • 21. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
    Lee HS; Kim MJ; An C
    Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification.
    Kim M; Hwang S; Ahn CS; Kim KH; Moon DB; Song GW; Jung DH; Hong SM
    Asian J Surg; 2021 Nov; 44(11):1389-1395. PubMed ID: 33766528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
    Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
    Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009-2021).
    Terai K; Ishigaki K; Kagawa Y; Okada K; Yoshida O; Sakurai N; Heishima T; Asano K
    J Am Vet Med Assoc; 2022 Apr; 260(13):1668-1674. PubMed ID: 35482569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
    Dageforde LA; Vachharajani N; Tabrizian P; Agopian V; Halazun K; Maynard E; Croome K; Nagorney D; Hong JC; Lee D; Ferrone C; Baker E; Jarnagin W; Hemming A; Schnickel G; Kimura S; Busuttil R; Lindemann J; Florman S; Holzner ML; Srouji R; Najjar M; Yohanathan L; Cheng J; Amin H; Rickert CA; Yang JD; Kim J; Pasko J; Chapman WC; Majella Doyle MB
    J Am Coll Surg; 2021 Apr; 232(4):361-371. PubMed ID: 33316425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study.
    Sasaki M; Sato Y; Nakanuma Y
    Virchows Arch; 2024 Jun; 484(6):915-923. PubMed ID: 38532197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
    Patil PA; Taddei T; Jain D; Zhang X
    Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
    Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An international multicentre evaluation of treatment strategies for combined hepatocellular-cholangiocarcinoma
    Claasen MPAW; Ivanics T; Beumer BR; de Wilde RF; Polak WG; Sapisochin G; IJzermans JNM
    JHEP Rep; 2023 Jun; 5(6):100745. PubMed ID: 37234277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
    Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
    Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma.
    Yang X; Chang J; Li R; Qi Y; Zeng X; Wang W; Li H
    J Hepatocell Carcinoma; 2023; 10():113-122. PubMed ID: 36727035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
    Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
    J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
    Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
    Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.
    Xiao Y; Zheng X; Zhou C; Huang P; Wu F; Yang C; Zeng M
    Eur Radiol; 2023 Feb; 33(2):1412-1421. PubMed ID: 36112193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality.
    Na HY; Kim JH; Kim H; Cho JY; Han HS; Jang ES; Kim JW; Jeong SH; Heo J; Kim JW; Kim JW; Ahn S
    Histopathology; 2024 Jan; 84(2):402-408. PubMed ID: 37903726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography.
    Li R; Yang D; Tang CL; Cai P; Ma KS; Ding SY; Zhang XH; Guo DY; Yan XC
    BMC Cancer; 2016 Feb; 16():158. PubMed ID: 26917546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma.
    Chu KJ; Kawaguchi Y; Wang H; Jiang XQ; Hasegawa K
    J Clin Transl Hepatol; 2024 Feb; 12(2):210-217. PubMed ID: 38343605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.
    Gurzu S; Szodorai R; Jung I; Banias L
    J Cancer Res Clin Oncol; 2024 May; 150(5):270. PubMed ID: 38780656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
    Zhou Q; Cai H; Xu MH; Ye Y; Li XL; Shi GM; Huang C; Zhu XD; Cai JB; Zhou J; Fan J; Ji Y; Sun HC; Shen YH
    Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):13-20. PubMed ID: 33160852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.